⚕ GalenOps CRO console
← SITE002 (USA)

SITE002-0193

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE002 (USA) (Dr. Nolan) · consented 2022-10-25
Adverse events
8
Serious AEs
1
Open data queries
0
Luna dropout signal
–

Adverse events

mild assessed 2026-08-18

Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-03-13 (study day 132); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-04-06 (study day 156); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-04-22 (study day 172); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-05-03 (study day 183); relationship: N

mild assessed 2026-08-18

Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-07-25 (study day 266); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-09-22 (study day 325); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-11-23 (study day 387); relationship: not assessed

severe serious assessed 2026-08-18

Grade 4 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2024-07-01 (study day 608); relationship: not assessed; serious criteria: life-threatening

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.